BMS has brought proceedings against AstraZeneca in the US District Court of Delaware for infringement of alleging that AstraZeneca’s Imfinzi® (durvalumab) infringes the patent relating to anti-PD-L1 antibodies. BMS also claims that ‘899 encompasses the BMS product Opdivo® (nivolumab).
The US District Court of Delaware has already set down BMS’ patent infringement case against AstraZeneca regarding Imfinzi® (durvalumab) as a jury trial in April 2024. It is unclear whether BMS intends to seek to have the two matters heard together.
Print Page Mail Article